Monitoring KAT6A-CREBBP measurable residual disease in t(8;16) therapy-related acute myeloid leukemia

Una Bhreathnach,Dearbhla Doherty,Karen Murphy,Catherine M. Flynn,Stephen E. Langabeer

Leukemia Research（2022）

引用 1|浏览1

暂无评分

摘要

•Therapy-related AML with the t(8;16) is uncommon and associated with a poor prognosis.•Hematopoietic allogeneic stem cell transplantation remains the only curative option.•KAT6A-CREBBP transcript identification is necessary for measurable residual disease.•RT-qPCR monitoring confirms the efficacy of allogeneic stem cell transplantation.•In t(8;16) AML, measurable residual disease peri-transplant may influence prognosis.

查看译文

关键词

Secondary AML,t(8,16),KAT6A-CREBBP,Allogeneic stem cell transplantation,Minimal Residual Disease

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要